NEW YORK, Jan. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), an international manufacturer and marketer of pharmaceutical
products, will release its Fiscal 2007 Third Quarter financial results
before the U.S. stock market opens on Tuesday, January 16, 2007. Later that
day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence
Olanoff, President and Chief Operating Officer and Frank Perier, Senior
Vice President and Chief Financial Officer, will discuss the financial
results and relevant company and industry topics. The conference call will
be webcast live beginning at 10:00 AM EST on the Company's website
http://www.frx.com and also on the website http://www.streetevents.com. Please log on to
either website at least fifteen minutes prior to the conference call as it
may be necessary to download software to access the call. A replay of the
conference call will be available until January 31, 2007 at both websites
and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291
(international investors), ID 5744720.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO)
About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical
company dedicated to identifying, developing, and delivering products that
make a positive difference in peoples' lives. Forest Laboratories' growing
product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated
for adults for the initial and maintenance treatment of major depressive
disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl),
an N-methyl- D-aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate and severe Alzheimer's disease; Benicar(R)*
(olmesartan medoxomil), an angiotensin receptor blocker, and Benicar*
HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor
blocker and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated in
combination with psychosocial support for the maintenance of abstinence
from alcohol in patients with alcohol dependence who are abstinent at
treatment initiation.
Except for the historical information contained herein, this release
contains "forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of risks
and uncertainties, including the difficulty of predicting FDA approvals,
the acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in the Company's
SEC reports, including the Company's Annual Report on Form 10-K for the
fiscal year ended March 31, 2006 and quarterly report filed on Form 10-Q
for the period ended September 30, 2006.
*Benicar is a registered trademark of Daiichi Sankyo, and Campral is a
registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
SOURCE FOREST LABORATORIES, INC.
 back to top
Related links:
http://www.frx.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President, Investor
Relations, of Forest Laboratories, Inc., +1-212-224-6714, or
charles.triano@frx.com
|
